Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Disease area: Pulmonary vascular diseases, Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
S. A. Hamidi, K. G. Dickman, S. Mathew, S. I. Said (Northport, Stony Brook, United States Of America). Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats. Eur Respir J 2005; 26: Suppl. 49, 4427

Member's Comments

No comment yet.

Related content which might interest you: Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008 Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH) Source: Annual Congress 2006 - Cellular mechanisms of airway disease Year: 2006 Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 High-altitude disease Source: Respipedia Article Year: 2017 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Role of anti-proliferative therapy in PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Stress failure plays a major role in the development of high-altitude pulmonary oedema in rats Source: Eur Respir J 2010; 35: 584-591 Year: 2010 Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition Source: Eur Respir J 2008; 31: 599-610 Year: 2008 Protection of vasoconstriction and lung function impairment by endothelin-receptor blockers and vasoactive intestinal peptide (VIP) in isolated perfused rat lungs Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007